Help appealing denials for this twice-yearly biologic for severe eosinophilic asthma.

Appeal Your Exdensur Denial

Get access to this ultra-long-acting IL-5 biologic for severe asthma.

Understanding Your Exdensur (depemokimab) Denial

Exdensur (depemokimab) is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype. Insurance denials often require documentation of eosinophil levels, prior biologic use, or step therapy requirements. If you have severe eosinophilic asthma, you deserve access to this innovative treatment.

Common Reasons for Denial

! Eosinophil levels not documented
! Must try other biologics first
! Step therapy requirement not met
! Prior authorization not obtained
! Not medically necessary
! Documentation of severe asthma inadequate

How We Help

We help you compile your eosinophil counts, asthma control scores, exacerbation history, and prior treatment records to demonstrate medical necessity for Exdensur.

Start your Exdensur appeal — it takes about 3 minutes.

Some Types of Evidence We Can Use For Supporting Your Appeal

✓ Depemokimab is an ultra-long-acting anti-IL-5 monoclonal antibody that provides sustained eosinophil suppression with twice-yearly dosing.

✓ Clinical trials demonstrated significant reduction in annual asthma exacerbation rates in patients with severe eosinophilic asthma.

✓ Severe eosinophilic asthma significantly impacts quality of life and can lead to frequent exacerbations, hospitalizations, and oral corticosteroid dependence.

✓ IL-5 pathway biologics are recommended by guidelines for patients with severe eosinophilic asthma uncontrolled on high-dose inhaled corticosteroids.

Patient Assistance & Copay Programs

These programs may help reduce your costs while you appeal:

GSK Patient Assistance Programs

GSK offers copay assistance (eligible patients may pay $0, up to $26,000/year) and patient assistance for uninsured patients. Call 1-866-728-4368.

Eligibility requirements and program terms may change. Please verify current details directly with each organization.

Patient Advocacy & Support Organizations

These organizations provide education, support, and advocacy for patients:

Asthma and Allergy Foundation of America

Leading patient advocacy organization for asthma and allergies, certified by National Health Council.

Allergy & Asthma Network

Nonprofit patient outreach, education, advocacy and research organization.

Frequently Asked Questions

Most insurers require documentation of blood eosinophils at 150 cells/mcL or higher at initiation or 300 cells/mcL or higher in the past 12 months. Your appeal should include lab results showing your eosinophil levels.

Some insurers require step therapy through other IL-5 pathway biologics first. However, you may appeal this requirement if you have specific reasons why Exdensur's twice-yearly dosing is medically necessary for you.

Ready to Fight Your Exdensur (depemokimab) Denial?

Our free AI-powered tool will help you generate a compelling appeal letter in minutes.

Start Your Appeal Chat with AI Assistant

Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program, including GlaxoSmithKline (GSK). All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.